HypertensionSOLUTION-PilotNCT07364175
A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults
A study testing Tirzepatide and Anti-Hypertensive medications in people with Hypertension and Obesity & Overweight, run by Cambridge University Hospitals NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
Hypertension is the leading risk factor for death globally, affecting approximately 30% of adults in the United Kingdom. Obesity is also a serious and ongoing epidemic, with global obesity rates having more than tripled in men and doubled in women, since 1975. Read more about this study
- Who is it for?
- Ages 18 to 40 years
- Conditions the study is for
- Hypertension, Obesity & Overweight
- What is being tested?
- Tirzepatide and Anti-Hypertensive medications
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Jan 2026to Jan 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Aged 18 to 40 years (inclusive)
- Body mass index (BMI) ≥27 kg/m2
- Clinical diagnosis of primary (essential) hypertension as per NICE guidance
- Unattended brachial SBP ≥135 and/or DBP ≥85 mmHg and <160/100 mmHg
- Maximum of one antihypertensive medication
- Written informed consent
Show all 11Show fewer
- Aged 18 to 40 years (inclusive)
- Body mass index ≥27 kg/m2
- Clinical diagnosis of primary (essential) hypertension as per NICE guidance
- Unattended brachial SBP ≥135 and/or DBP ≥85 mmHg and <160/100 mmHg
- Maximum of one antihypertensive medication
Who cannot join
- Anything in medical notes suggesting unsuitable in the opinion of the investigator
- Eligibility criteria for participation in weight loss arm
- The presence of any of the following will preclude participant inclusion:
- Known or suspected secondary hypertension
- Hypersensitivity to any of the study drugs or excipients
- Currently taking drugs likely to have interactions with tirzepatide
Show all 26Show fewer
- Diagnosis of type 1 or type 2 diabetes mellitus or current usage of insulin or other injectable drugs for the treatment of diabetes such as but not limited to GLP-1 and GIP receptor agonists
- Prior or planned surgical, endoscopic and/or device-based therapy treatment for obesity
- Self-reported, intentional or unintentional, change in body weight (over ~10%) within ~three months of screening
- Known heart failure or clinically significant valvular heart disease
- Implanted pacemaker or implantable cardioverter defibrillator (ICD)
- Second or third-degree AV block, sino-atrial block, sick sinus syndrome
- Known active malignancy including thyroid cancer
- Known renal impairment (creatinine >150µmol/L)
- Clinically significant neurological disease
- History of scleroderma
- Participants on anticoagulant therapy
- Known history of pancreatitis
- Known inflammatory bowel disease
- History of gallstones (unless previous cholecystectomy)
- Severe gastroparesis or gastric emptying abnormality
- Family history of multiple endocrine neoplasia
- Needle-phobia
- Planned pregnancy, current pregnancy, or breastfeeding
- Current involvement in the active treatment phase of other research studies
- Any other clinical reason which may preclude entry in the opinion of the investigator
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, CB2 0QQ
James Goodman, MRCP PhD, +44 01223 336806, james.goodman11@nhs.net
About this study
Official title: Standard of Care or Weight Loss Drug Therapy in Obesity-related Hypertension - Pilot Study
Hypertension is the leading risk factor for death globally, affecting approximately 30% of adults in the United Kingdom. Obesity is also a serious and ongoing epidemic, with global obesity rates having more than tripled in men and doubled in women, since 1975. In the United Kingdom, 64% of the adult population are overweight or obese. Hypertension and obesity share a well-established association, with obesity being responsible for the development of hypertension in 40-78% of cases. In young adults, this link between body size and blood pressure (BP) is much stronger that in older adults. Since overweight and obesity are among the most common and modifiable causes of high BP, weight loss induced by lifestyle-changes is recommended for overweight or obese patients with hypertension. However, lifestyle interventions, even when successful, result in only moderate weight loss, which is not maintained in the majority of cases. A meta-analysis of randomised controlled trials demonstrated that lifestyle-interventions lead to an average net weight reduction of 5.1 kg, accompanied by a significant, but modest, ~4 mmHg reduction in BP. Weight loss interventions could play a crucial role in the treatment of obesity-related hypertension in young adults.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, originally developed for the treatment of type 2 diabetes, are safe and clinically effective anti-obesity drugs. Recent data show a 10-20% placebo-adjusted reduction in body weight in overweight or obese adults without diabetes using the GLP-1 analogue semaglutide or the dual GLP-1/GIP receptor agonist tirzepatide, with the majority of weight loss achieved within the initial six months. The substantial weight loss induced by these drugs is accompanied by a significant reduction in BP. Two recent meta-analyses showed that semaglutide is associated with a ~5 mmHg placebo-adjusted reduction in clinic systolic BP (SBP). A sub-study of the SURMOUNT-1 trial reported a ~10 mmHg reduction in 24-h ambulatory SBP with tirzepatide. Most participants in these studies were normotensive or had well-controlled hypertension. Furthermore, antihypertensive medication use declined amongst those receiving anti-obesity drugs meaning the BP-lowering effect of weight loss, elicited by these drugs, is probably underestimated. These data suggest that the new anti-obesity drugs could be effective in managing overweight or obesity-related hypertension. Furthermore, it may be possible to cure hypertension in at least some young adults, removing the need for life-long antihypertensive treatment. However, the magnitude and time course of BP reduction elicited by these new anti-obesity drugs remain uncertain.
The primary aim of this feasibility study is to assess the extent and trajectory of BP reduction achieved through intensive weight loss in overweight or obese adults with stage 1 hypertension and compare this to current standard of care measures which uses anti-hypertensive medications and lifestyle advice. The study will utilise a modified trial within cohort approach, using patients based within the clinical pharmacology/hypertension service at Addenbrooke's Hospital, Cambridge.
- Conditions
- Hypertension, Obesity & Overweight
- Being tested
- Tirzepatide, Anti-Hypertensive medications
- Keywords
- hypertension, obesity, overweight, tirzepatide, GLP-1
- Medical subject headings
- Hypertension, Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TirzepatideDrug
2.5mg for 4 weeks, 5mg for 4 weeks, 7.5mg for 4 weeks, 10mg for 12 weeks
Anti-Hypertensive medicationsDrug
Anti-hypertensive drug therapy as per local and national guidelines
| Study group | Role | What they receive |
|---|---|---|
| Tirzepatide [weight loss arm] | Experimental | 6 months of treatment with a combined GLP-1/GIP receptor agonist, tirzepatide Receives: Drug: Tirzepatide |
| Lifestyle advice and anti-hypertensive medications [standard of Care arm] | Active comparator | Not described Receives: Drug: Anti-Hypertensive medications |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ambulatory systolic blood pressure
Change in daytime ambulatory systolic blood pressure in the weight loss arm
Measured: Baseline to week 24
Secondary outcomes (55)
Ambulatory diastolic blood pressure
Change in daytime ambulatory diastolic blood pressure in the weight loss arm
Measured: Baseline to week 24
Clinic systolic blood pressure
Changes in clinic systolic blood pressure in the weight loss arm
Measured: Baseline to week 24
Clinic diastolic blood pressure
Changes in clinic diastolic blood pressure in the weight loss arm
Measured: Baseline to week 24
Clinic mean arterial pressure
Changes in clinic mean arterial pressure in the weight loss arm
Measured: Baseline to week 24
Unattended systolic blood pressure
Changes in unattended systolic blood pressure in the weight loss arm
Measured: Baseline to week 24
Unattended diastolic blood pressure
Changes in unattended diastolic blood pressure in the weight loss arm
Measured: Baseline to week 24
Unattended mean arterial pressure
Changes in unattended mean arterial pressure in the weight loss arm
Measured: Baseline to week 24
Body weight
Changes in body weight in the weight loss arm
Measured: Baseline to week 24
Body fat
Changes in body fat in the weight loss arm
Measured: Baseline to week 24
Waist:hip ratio
Changes in waist:hip ratio in the weight loss arm
Measured: Baseline to week 24
Cardiac output
Changes in cardiac output in the weight loss arm
Measured: Baseline to week 24
Peripheral vascular resistance
Changes in peripheral vascular resistance in the weight loss arm
Measured: Baseline to week 24
Pulse wave analysis / pulse wave velocity
Changes in markers of pulse wave analysis and pulse wave velocity in the weight loss arm
Measured: Baseline to week 24
Heart rate variability
Changes in heart rate variability in the weight loss arm
Measured: Baseline to week 24
Renin
Changes in plasma renin in the weight loss arm
Measured: Baseline to week 24
Aldosterone
Changes in plasma aldosterone in the weight loss arm
Measured: Baseline to week 24
Plasma metanephrines
Changes in plasma metanephrines in the weight loss arm
Measured: Baseline to week 24
Leptin
Changes in leptin in the weight loss arm
Measured: Baseline to week 24
Insulin
Changes in plasma insulin in the weight loss arm
Measured: Baseline to week 24
Lipid profile
Changes in the lipid profile in the weight loss arm
Measured: Baseline to week 24
HbA1C
Changes in HbA1C in the weight loss arm
Measured: Baseline to week 24
Estimated glomerular filtration rate
Changes in eGFR in the weight loss arm
Measured: Baseline to week 24
N-terminal pro-B-type natriuretic peptide
Changes in NT-proBNP in the weight loss arm
Measured: Baseline to week 24
Urine albumin:creatinine ratio
Change in urine albumin:creatinine ratio in the weight loss arm
Measured: Baseline to week 24
24-hour urine sodium
Change in 24-hour urine sodium in the weight loss arm
Measured: Baseline to week 24
24-hour urine aldosterone
Change in 24-hour urine aldosterone in the weight loss arm
Measured: Baseline to week 24
Antihypertensive medications
Change in number of antihypertensive medications
Measured: Baseline to week 24
Quality of life measures
Changes in quality of life questionnaire scores in the weight loss arm
Measured: Baseline to week 24
Ambulatory systolic blood pressure
Between-group comparison in ambulatory sytolic blood pressure
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Ambulatory diastolic blood pressure
Between-group comparison in ambulatory diastolic blood pressure
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Clinic systolic blood pressure
Between-group comparison in clinic systolic blood pressure
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Clinic diastolic blood pressure
Between-group comparison in clinic diastolic blood pressure
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Clinic mean arterial pressure
Between-group comparison in clinic mean arterial pressure
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Unattended systolic blood pressure
Between-group comparison in unattended systolic blood pressure
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Unattended diastolic blood pressure
Between-group comparison in unattended diastolic blood pressure
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Unattended mean arterial pressure
Between-group comparison in mean arterial pressure
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Body weight
Between-group body weight
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Body fat
Between-group comparison in body fat
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Waist:hip ratio
Between-group comparison in waist:hip ratio
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Cardiac output
Between-group comparison in cardiac output
Measured: At week 24 (weight loss arm) and 6 months (standard of care arm)
Peripheral vascular resistance
Between-group comparison in peripheral vascular resistance
Measured: At week 24 (weight loss arm) and 6 months (standard of care arm)
Pulse wave analysis / pulse wave velocity
Between-group comparison in markers of pulse wave analysis and pulse wave velocity
Measured: At week 24 (weight loss arm) and 6 months (standard of care arm)
Heart rate variability
Between-group comparison in heart rate variability
Measured: At week 24 (weight loss arm) and 6 months (standard of care arm)
Plasma renin
Between-group comparison in plasma renin
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Plasma aldosterone
Between-group comparison in plasma aldosterone
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Plasma metanephrines
Between-group comparison in plasma metanephrines
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Lipid profile
Between-group comparison in lipid profile
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
HbA1C
Between-group comparison in HbA1C
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Estimated glomerular filtration rate
Between-group comparison in eGFR
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
N-terminal pro-B-type natriuretic peptide
Between-group comparison in NT-proBNP
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Urine albumin:creatinine ratio
Between-group comparison in urine albumin:creatinine ratio
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
24-hour urine sodium
Between-group comparison in 24-hour urine sodium
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
24-hour urine aldosterone
Between-group comparison in 24-hour urine aldosterone
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Number of antihypertensive medications
Between-group comparison in the number of anti-hypertensive medications
Measured: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Quality of life measures
Between-group comparison in quality of life questionnaire scores
Measured: At week 24 (weight loss arm) and 6 months (standard of care arm)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2026
- Study startJan 2026 (estimated)
- Primary completionJan 2027 (estimated)
- Study completionJan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study will utilise a modified trial within cohort (TwiC) design for patients under the hypertension/clinical pharmacology clinic. Those who meet the eligibility criteria for randomisation will be randomised to being approached for either: (i) 6 months of treatment with a combined GLP-1/GIP receptor agonist, Tirzepatide \[Group A - Weight loss arm\] (ii) Standard anti-hypertensive treatment and attendance at a 6-month combined research/clinical follow-up visit \[Group B - Standard of Care (SoC) arm\].
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom
- Responsible party
- Principal investigator, James Goodman, Cambridge University Hospitals NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07364175
- Sponsor's protocol ID
- R+D: A097457, REC: 25/WA/0268
- Acronym
- SOLUTION-Pilot
- Status last verified
- Jan 2026
- First submitted
- 6 Jan 2026
- Last updated
- 29 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Following publication, the data that support the findings of this study will be available from the Chief Investigator/corresponding author upon reasonable request
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Standard of Care or Weight Loss Drug Therapy in Obesity-related Hypertension - Pilot Study
- ClinicalTrials.gov ID
- NCT07364175
- Acronym / sponsor ID
- SOLUTION-Pilot / R+D: A097457, REC: 25/WA/0268
- Conditions
- Hypertension, Obesity & Overweight
- Keywords
- hypertension, obesity, overweight, tirzepatide, GLP-1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Cambridge University Hospitals NHS Foundation TrustUniversity, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom
- Study start
- Jan 2026 (estimated)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2029 (estimated)
- First posted
- 23 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hypertension is the leading risk factor for death globally, affecting approximately 30% of adults in the United Kingdom. Obesity is also a serious and ongoing epidemic, with global obesity rates having more than tripled in men and doubled in women, since 1975. In the United Kingdom, 64% of the adult population are overweight or obese. Hypertension and obesity share a well-established association, with obesity being responsible for the development of hypertension in 40-78% of cases. In young adults, this link between body size and blood pressure (BP) is much stronger that in older adults. Since overweight and obesity are among the most common and modifiable causes of high BP, weight loss induced by lifestyle-changes is recommended for overweight or obese patients with hypertension. However, lifestyle interventions, even when successful, result in only moderate weight loss, which is not maintained in the majority of cases. A meta-analysis of randomised controlled trials demonstrated that lifestyle-interventions lead to an average net weight reduction of 5.1 kg, accompanied by a significant, but modest, ~4 mmHg reduction in BP. Weight loss interventions could play a crucial role in the treatment of obesity-related hypertension in young adults.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, originally developed for the treatment of type 2 diabetes, are safe and clinically effective anti-obesity drugs. Recent data show a 10-20% placebo-adjusted reduction in body weight in overweight or obese adults without diabetes using the GLP-1 analogue semaglutide or the dual GLP-1/GIP receptor agonist tirzepatide, with the majority of weight loss achieved within the initial six months. The substantial weight loss induced by these drugs is accompanied by a significant reduction in BP. Two recent meta-analyses showed that semaglutide is associated with a ~5 mmHg placebo-adjusted reduction in clinic systolic BP (SBP). A sub-study of the SURMOUNT-1 trial reported a ~10 mmHg reduction in 24-h ambulatory SBP with tirzepatide. Most participants in these studies were normotensive or had well-controlled hypertension. Furthermore, antihypertensive medication use declined amongst those receiving anti-obesity drugs meaning the BP-lowering effect of weight loss, elicited by these drugs, is probably underestimated. These data suggest that the new anti-obesity drugs could be effective in managing overweight or obesity-related hypertension. Furthermore, it may be possible to cure hypertension in at least some young adults, removing the need for life-long antihypertensive treatment. However, the magnitude and time course of BP reduction elicited by these new anti-obesity drugs remain uncertain.
The primary aim of this feasibility study is to assess the extent and trajectory of BP reduction achieved through intensive weight loss in overweight or obese adults with stage 1 hypertension and compare this to current standard of care measures which uses anti-hypertensive medications and lifestyle advice. The study will utilise a modified trial within cohort approach, using patients based within the clinical pharmacology/hypertension service at Addenbrooke's Hospital, Cambridge.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The study will utilise a modified trial within cohort (TwiC) design for patients under the hypertension/clinical pharmacology clinic. Those who meet the eligibility criteria for randomisation will be randomised to being approached for either: (i) 6 months of treatment with a combined GLP-1/GIP receptor agonist, Tirzepatide [Group A - Weight loss arm] (ii) Standard anti-hypertensive treatment and attendance at a 6-month combined research/clinical follow-up visit [Group B - Standard of Care (SoC) arm].
| Arm | Type | Receives |
|---|---|---|
| Tirzepatide [weight loss arm] | Experimental | Drug: Tirzepatide6 months of treatment with a combined GLP-1/GIP receptor agonist, tirzepatide |
| Lifestyle advice and anti-hypertensive medications [standard of Care arm] | Active comparator | Drug: Anti-Hypertensive medications |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (11 listed)
- Aged 18 to 40 years (inclusive)
- Body mass index (BMI) ≥27 kg/m2
- Clinical diagnosis of primary (essential) hypertension as per NICE guidance
- Unattended brachial SBP ≥135 and/or DBP ≥85 mmHg and <160/100 mmHg
- Maximum of one antihypertensive medication
Key exclusion criteria (26 listed)
- Anything in medical notes suggesting unsuitable in the opinion of the investigator
- Eligibility criteria for participation in weight loss arm
- Known or suspected secondary hypertension
- Hypersensitivity to any of the study drugs or excipients
- Currently taking drugs likely to have interactions with tirzepatide
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tirzepatide2.5mg for 4 weeks, 5mg for 4 weeks, 7.5mg for 4 weeks, 10mg for 12 weeks | Drug | Tirzepatide [weight loss arm] |
| Anti-Hypertensive medicationsAnti-hypertensive drug therapy as per local and national guidelines | Drug | Lifestyle advice and anti-hypertensive medications [standard of Care arm] |
Primary outcome
Ambulatory systolic blood pressure
Time frame: Baseline to week 24
Change in daytime ambulatory systolic blood pressure in the weight loss arm
55 secondary outcomes
Ambulatory diastolic blood pressure
Time frame: Baseline to week 24
Clinic systolic blood pressure
Time frame: Baseline to week 24
Clinic diastolic blood pressure
Time frame: Baseline to week 24
Clinic mean arterial pressure
Time frame: Baseline to week 24
Unattended systolic blood pressure
Time frame: Baseline to week 24
Unattended diastolic blood pressure
Time frame: Baseline to week 24
Unattended mean arterial pressure
Time frame: Baseline to week 24
Body weight
Time frame: Baseline to week 24
Body fat
Time frame: Baseline to week 24
Waist:hip ratio
Time frame: Baseline to week 24
Cardiac output
Time frame: Baseline to week 24
Peripheral vascular resistance
Time frame: Baseline to week 24
Pulse wave analysis / pulse wave velocity
Time frame: Baseline to week 24
Heart rate variability
Time frame: Baseline to week 24
Renin
Time frame: Baseline to week 24
Aldosterone
Time frame: Baseline to week 24
Plasma metanephrines
Time frame: Baseline to week 24
Leptin
Time frame: Baseline to week 24
Insulin
Time frame: Baseline to week 24
Lipid profile
Time frame: Baseline to week 24
HbA1C
Time frame: Baseline to week 24
Estimated glomerular filtration rate
Time frame: Baseline to week 24
N-terminal pro-B-type natriuretic peptide
Time frame: Baseline to week 24
Urine albumin:creatinine ratio
Time frame: Baseline to week 24
24-hour urine sodium
Time frame: Baseline to week 24
24-hour urine aldosterone
Time frame: Baseline to week 24
Antihypertensive medications
Time frame: Baseline to week 24
Quality of life measures
Time frame: Baseline to week 24
Ambulatory systolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Ambulatory diastolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Clinic systolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Clinic diastolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Clinic mean arterial pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Unattended systolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Unattended diastolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Unattended mean arterial pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Body weight
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Body fat
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Waist:hip ratio
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Cardiac output
Time frame: At week 24 (weight loss arm) and 6 months (standard of care arm)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2026.
- Individual participant dataSharing planned: Yes. Following publication, the data that support the findings of this study will be available from the Chief Investigator/corresponding author upon reasonable request
Related trials for Hypertension
Not yet recruitingPhase 3
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Not yet recruitingObservational study
Intra-Abdominal Pressure, Respiratory Mechanics, and Ventilator Liberation After Emergency Major Laparotomy
Intra-Abdominal Hypertension, Respiratory Mechanics
Enrolling by invitation
MTM2MTG Pilot Ancillary Study
Diet, Healthy, HbA1c
RecruitingObservational study
Natural History of Noncirrhotic Portal Hypertension
Cystic Fibrosis, Immunologic Deficiency Syndrome
RecruitingPhase 2
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Pheochromocytoma, Paraganglioma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tirzepatide and Anti-Hypertensive medications in people with Hypertension and Obesity & Overweight, run by Cambridge University Hospitals NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ambulatory systolic blood pressure (time frame: Baseline to week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2026.